Vitamin D3 for Life

Live Enlightened

Article

Vitamin D Insufficiency: Physiology, Thresholds and Interpretation: Evidence Synthesis

Previous related pageVitamin D Insufficiency as a Functional Intermediate State: Study SummaryNext related pageVitamin D Thresholds and Targets: Physiology, Clinical Meaning and Research Interpretation: Evidence Synthesis
Study at a glance

What does the research say about vitamin D insufficiency?

It does not identify one intermediate blood range that represents the same problem in everyone. Concern generally becomes clearer as vitamin D becomes very low and stays low, while the meaning of intermediate results is less certain.

Can calcium remain normal when vitamin D is low?

Yes. The body can adjust hormones and calcium handling to maintain blood calcium. A normal calcium result therefore does not, by itself, establish adequate vitamin D supply.

Do calcium absorption studies identify one ideal vitamin D level?

No. The studies discussed here did not find a single boundary that reliably separated good and poor calcium absorption in everyone. Their findings also do not make severe vitamin D deficiency harmless.

Does an insufficiency label automatically mean a higher target is better?

No. Showing that a result falls below a chosen boundary is different from showing that raising it to a particular higher level improves health. That benefit needs evidence of its own.

Read the full article below ↓

Vitamin D insufficiency occupies an awkward but important place between clearly adequate vitamin D supply and the more established consequences of severe deficiency. The evidence does not support treating insufficiency as one universal disease state with a single biological cut-off. It does, however, support a physiological continuum in which falling 25-hydroxyvitamin D [25(OH)D] can increase reliance on compensatory mechanisms before overt abnormalities become consistently apparent. Understanding that distinction brings together the physiological and interpretive questions developed in Vitamin D Insufficiency Explained: what lower vitamin D supply can mean biologically, why different thresholds have been proposed, and why the same numerical result can be classified differently under different frameworks.

The evidence supports a continuum more strongly than a fixed intermediate compartment

Circulating 25(OH)D is a useful indicator of vitamin D supply, but it is not a direct measure of every downstream vitamin D effect. As substrate availability falls, the endocrine system can compensate through changes in parathyroid hormone (PTH), calcium conservation and regulated production of active 1,25-dihydroxyvitamin D. Serum calcium can therefore remain within its normal range even while vitamin D supply is becoming progressively more constrained.

This is the strongest physiological basis for describing an intermediate state. There need not be an abrupt transition from “normal” to “deficient.” Instead, lower vitamin D supply can progressively increase regulatory demand before the classical manifestations of prolonged severe deficiency emerge. The distinction between measured status and downstream biological action is explored more broadly in Vitamin D Status vs Vitamin D Effect.

That continuum does not by itself establish the familiar laboratory category of 20 to 30 ng/mL as a discrete physiological state. To justify such a boundary biologically, one would expect an outcome such as PTH suppression, calcium absorption or bone metabolism to change consistently near the same 25(OH)D concentration across different populations. The evidence is considerably less tidy.

PTH shows increasing physiological pressure but not one universal threshold

The inverse relationship between 25(OH)D and PTH is central to the historical insufficiency concept. When vitamin D supply is low enough to make calcium economy less secure, PTH can increase to help preserve serum calcium. This makes PTH a plausible functional indicator of increasing physiological strain.

Sai and colleagues examined this relationship in 488 older women and also reviewed 70 published studies. Their own data showed an inverse relationship between 25(OH)D and PTH, but not a discrete concentration at which PTH suddenly became maximally suppressed. Across the wider literature, reported thresholds varied substantially. In the same cohort, bone-turnover markers became more adverse below about 18 ng/mL (45 nmol/L), suggesting that lower concentrations carried greater physiological significance without supporting 30 ng/mL as a universal boundary.

The important synthesis is therefore not that PTH is irrelevant, but that a graded biological relationship has sometimes been converted into a categorical one. PTH supports the idea that progressively falling vitamin D supply can matter. It does not establish that every individual crosses from functional adequacy to insufficiency at the same 25(OH)D concentration.

This distinction is central to Vitamin D Thresholds vs Targets. A threshold can be useful for classification or policy even when the underlying physiological response is continuous.

Calcium absorption weakens the case for a universal 30 ng/mL boundary

Intestinal calcium absorption has also been used to justify higher definitions of vitamin D sufficiency. If calcium absorption consistently deteriorated below approximately 30 ng/mL and improved above it, that would provide a strong physiological argument for treating the intermediate range as a distinct functional state.

Hansen and colleagues directly tested this proposition in postmenopausal women whose 25(OH)D concentrations were classified as insufficient. Fractional calcium absorption was measured using dual stable calcium isotopes before and after vitamin D repletion. The study specifically asked whether correcting conventional vitamin D insufficiency produced a meaningful improvement in calcium absorption. The results did not support the assumption that every person within the commonly labelled insufficiency range has a substantial calcium-absorption defect.

Gallagher and colleagues extended this question in a one-year randomised study involving 163 postmenopausal women assigned to placebo or graded doses of vitamin D3 while calcium intake was controlled. Vitamin D supplementation produced substantial differences in 25(OH)D, but the absolute increase in calcium absorption was small. The investigators found no evidence of a reduced-absorption threshold between approximately 10 and 66 ng/mL.

Together, these studies are important because they separate severe deficiency physiology from a broad intermediate classification. Very low vitamin D supply can impair mineral handling, but the evidence does not show that the commonly used 20 to 30 ng/mL band behaves as a uniform calcium-malabsorption state. A 25(OH)D result is therefore informative about vitamin D status without functioning as a direct meter of intestinal calcium absorption. That broader distinction is developed in What Vitamin D Levels Represent.

Large clinical datasets place clearer biochemical disturbance lower

Evidence from large clinical populations also challenges the idea that the entire traditional insufficiency range represents one pathological condition. Shah and colleagues analysed 11,855 adults and examined relationships between 25(OH)D and calcium, phosphate, alkaline phosphatase and PTH. Their analysis identified a biochemical breakpoint below approximately 30 nmol/L, equivalent to about 12 ng/mL.

The same study did not demonstrate deleterious skeletal associations throughout the broad 30 to 75 nmol/L range that had frequently been labelled vitamin D insufficiency. Even below the lower breakpoint, not every individual showed every biochemical abnormality. The result therefore reinforces two points at once: very low vitamin D concentrations deserve greater physiological concern, but biological consequences remain probabilistic rather than appearing simultaneously in everyone at a single numerical threshold.

This evidence aligns more naturally with Vitamin D Deficiency Definitions than with a rigid three-compartment model. The transition toward classical deficiency becomes more convincing as concentrations fall, while the intermediate zone contains progressively greater uncertainty and individual variation.

Different guideline thresholds are partly answering different questions

The interpretive difficulty becomes clearer when physiological evidence is compared with major guideline frameworks. Different organisations have not simply looked at the same biological switch and reported different numbers. They have used different outcomes, purposes and standards of evidence.

The 2011 Institute of Medicine framework based vitamin D requirements primarily on skeletal health and concluded that a serum 25(OH)D concentration of at least 20 ng/mL (50 nmol/L) would meet the requirements of at least 97.5% of the North American population under the assumptions used to establish the dietary reference intakes. It did not treat 30 ng/mL as a necessary population adequacy threshold and cautioned that higher concentrations were not consistently associated with greater benefit.

The Endocrine Society’s 2011 clinical practice guideline used a different framework. It defined vitamin D deficiency as below 20 ng/mL, insufficiency as 21 to 29 ng/mL and sufficiency as 30 ng/mL or higher. That classification became highly influential in clinical and public discussion and helped establish the familiar 20 to 30 ng/mL insufficiency band.

These two approaches were not interchangeable. One centred on population nutrient requirements and skeletal-health evidence, while the other adopted a clinical classification intended to identify and manage people considered at risk of deficiency. Treating the difference simply as a dispute over which laboratory number is “correct” obscures the different purposes behind the thresholds. The wider problem is examined in Why Vitamin D Deficiency Cut-Offs Differ Between Guidelines.

The 2024 Endocrine Society position materially changes the insufficiency debate

The 2024 Endocrine Society guideline represents an important change in interpretation. Rather than assuming that established 25(OH)D categories identify concentrations at which generally healthy people should be tested or treated, the guideline examined whether clinical trials demonstrated outcome-specific thresholds for benefit from vitamin D supplementation.

For the generally healthy populations within its scope, the panel concluded that available trial evidence did not establish 25(OH)D thresholds that could reliably identify who would benefit from supplementation beyond the guideline’s population recommendations. Routine 25(OH)D testing was therefore not recommended for several generally healthy groups.

An accompanying Endocrine Society guideline communication made the interpretive change especially explicit. The Society no longer endorsed its previous definition of vitamin D sufficiency as at least 30 ng/mL or the previous 20 to 30 ng/mL category of vitamin D insufficiency as an actionable designation for generally healthy individuals.

This does not demonstrate that intermediate vitamin D status is biologically meaningless. Nor does it prove that no threshold can ever be useful for any clinical population or outcome. It shows that the older 20 to 30 ng/mL category should not be treated as though clinical trial evidence has established it as a universal treatment boundary.

UK guidance illustrates a different population-protection approach

The UK Scientific Advisory Committee on Nutrition reached a different operational threshold through a population-health framework. SACN concluded that the risk of poor musculoskeletal health increases below 25 nmol/L and used 25 nmol/L as a population-protective concentration when deriving the UK reference nutrient intake.

SACN did not present 25 nmol/L as a precise point at which every individual develops vitamin D deficiency disease. It was a protective population benchmark derived from the evidence considered relevant to musculoskeletal health. That is fundamentally different from asserting that every concentration below a higher boundary represents physiological insufficiency.

The contrast between 25, 50 and 75 nmol/L thresholds therefore cannot be resolved simply by selecting the highest value as the safest or the lowest as the most conservative. Their meaning depends on what each boundary was designed to represent. Population Reference Ranges Explained provides the wider framework for understanding why group-level boundaries do not map perfectly onto individual physiological requirements.

Measurement uncertainty makes narrow categories even less absolute

Even if every guideline used the same threshold, interpretation would still be complicated by biological and analytical variability. 25(OH)D changes with season, sunlight exposure, intake, body composition and other physiological circumstances. Laboratory methods also introduce variation. A person whose measured value lies close to a classification boundary can therefore move from one category to another without experiencing an equivalent step-change in biological function.

This is particularly important for the historical insufficiency band because relatively small differences in measured 25(OH)D can determine whether a result is labelled deficient, insufficient or sufficient. Biological Noise in Vitamin D Testing, Limitations of Vitamin D Blood Tests and Why Vitamin D Results Differ explain why those category changes should not automatically be interpreted as equally abrupt biological changes.

Insufficiency is most defensible as a contextual intermediate descriptor

Across the evidence, several findings converge. Very low 25(OH)D concentrations are more consistently associated with adverse mineral physiology than intermediate concentrations. PTH can rise as vitamin D supply falls, but there is no single universal suppression threshold. Direct calcium-absorption studies do not demonstrate a consistent 30 ng/mL functional boundary. Large observational datasets identify clearer biochemical disturbance at substantially lower concentrations than the traditional upper insufficiency threshold. Major organisations have adopted different numerical boundaries because they have used different questions and evidentiary frameworks.

These findings support the physiological idea of an intermediate state more strongly than they support one universal intermediate band. Vitamin D supply can become progressively less secure before severe deficiency is reached, and compensatory physiology can become increasingly important during that transition. But the exact concentration at which those changes become materially important differs between people, endpoints and study designs.

That makes “insufficiency” most useful as a contextual descriptor rather than a stand-alone diagnosis. It can identify a region in which vitamin D supply is lower than a chosen reference or policy level and in which physiological vulnerability may be increasing. It cannot, from the number alone, establish that a particular tissue is dysfunctional, that every person requires treatment to reach a higher target, or that moving slightly across a category boundary represents a major biological transition.

Deficiency, insufficiency and sufficiency remain useful only when their purpose is explicit

The practical interpretation of vitamin D status therefore begins by asking what a category is intended to accomplish. A threshold designed to identify risk of classical deficiency is not necessarily the same as a population nutrient benchmark. A population adequacy concentration is not necessarily an individual treatment target. A concentration above a deficiency threshold does not guarantee optimal function for every possible endpoint, while a concentration below a higher sufficiency target does not automatically establish disease.

Vitamin D Sufficiency Explained is therefore the necessary counterpart to insufficiency: sufficiency also has to be defined in relation to the purpose and evidence behind the boundary. The categories become misleading when they are treated as intrinsic properties of the blood concentration rather than interpretive frameworks applied to it.

The combined evidence supports a cautious hierarchy of confidence. Severe and prolonged vitamin D deficiency has well-established consequences for mineral metabolism and bone mineralisation. Progressively lower vitamin D supply above that severe range can plausibly increase compensatory demand and physiological vulnerability. The precise boundaries of an “insufficient” state, however, are much less certain and are not universally established by PTH, calcium absorption, biochemical outcomes or supplementation trials.

Vitamin D insufficiency is therefore neither a meaningless label nor a universally defined disease. It is best understood as an interpretive description placed on a biological continuum. Its value depends on preserving that distinction.

Scientific sources and publication details

Karen E Hansen et al. Vitamin D Insufficiency: Disease or No Disease?. Journal of Bone and Mineral Research. 2008;23(7):1052 to 1060. PMID 18302509; PMCID PMC2574556; DOI 10.1359/JBMR.080230.

A J Sai et al. Relationship between Vitamin D, Parathyroid Hormone, and Bone Health. Journal of Clinical Endocrinology & Metabolism. 2011;96(3):E436: E446. PMID 21159838; PMCID PMC3047227; DOI 10.1210/jc.2010-1886.

J Christopher Gallagher et al. The Effect of Vitamin D on Calcium Absorption in Older Women. Journal of Clinical Endocrinology & Metabolism. 2012;97(10):3550 to 3556. PMID 22855333; PMCID PMC3462946; DOI 10.1210/jc.2012-2020.

Sonali Shah et al. Serum 25-Hydroxyvitamin D Insufficiency in Search of a Bone Disease. Journal of Clinical Endocrinology & Metabolism. 2017;102(7):2321 to 2328. PMID 28379394; DOI 10.1210/jc.2016-3189.

A Catharine Ross et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. Journal of Clinical Endocrinology & Metabolism. 2011;96(1):53 to 58. PMID 21118827; PMCID PMC3046611; DOI 10.1210/jc.2010-2704.

Michael F Holick et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96(7):1911 to 1930. DOI 10.1210/jc.2011-0385. Historical guideline; replaced by the 2024 guideline.

Marie B Demay et al. Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1907 to 1947. PMID 38828931; DOI 10.1210/clinem/dgae290. Corrected online.

Christopher R McCartney et al. Vitamin D Insufficiency and Epistemic Humility: An Endocrine Society Guideline Communication. Journal of Clinical Endocrinology & Metabolism. 2024;109(8):1948 to 1954.

Scientific Advisory Committee on Nutrition. SACN vitamin D and health report. UK Scientific Advisory Committee on Nutrition. 2016; current UK population guidance remains based on this report.

Related reading

Original sources

Source

Vitamin D Insufficiency: Disease or No Disease?

Published in Journal of Bone and Mineral Research (2008).

Publication details

Karen E Hansen et al. Vitamin D Insufficiency: Disease or No Disease?. Journal of Bone and Mineral Research. 2008;23(7):1052 to 1060. PMID 18302509; PMCID PMC2574556; DOI 10.1359/JBMR.080230.

Read more →
Source

The Effect of Vitamin D on Calcium Absorption in Older Women

Published in Journal of Clinical Endocrinology & Metabolism (2012).

Publication details

J Christopher Gallagher et al. The Effect of Vitamin D on Calcium Absorption in Older Women. Journal of Clinical Endocrinology & Metabolism. 2012;97(10):3550 to 3556. PMID 22855333; PMCID PMC3462946; DOI 10.1210/jc.2012-2020.

Read more →
Source

The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know

Published in Journal of Clinical Endocrinology & Metabolism (2011).

Publication details

A Catharine Ross et al. The 2011 Report on Dietary Reference Intakes for Calcium and Vitamin D from the Institute of Medicine: What Clinicians Need to Know. Journal of Clinical Endocrinology & Metabolism. 2011;96(1):53 to 58. PMID 21118827; PMCID PMC3046611; DOI 10.1210/jc.2010-2704.

Read more →
Source

Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline

Published in Journal of Clinical Endocrinology & Metabolism (2011).

Publication details

Michael F Holick et al. Evaluation, Treatment, and Prevention of Vitamin D Deficiency: an Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism. 2011;96(7):1911 to 1930. DOI 10.1210/jc.2011-0385. Historical guideline; replaced by the 2024 guideline.

Read more →
Source

SACN vitamin D and health report

Published in UK Scientific Advisory Committee on Nutrition (2016).

Publication details

Scientific Advisory Committee on Nutrition. SACN vitamin D and health report. UK Scientific Advisory Committee on Nutrition. 2016; current UK population guidance remains based on this report.

Read more →